Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Strens (Leuven, Belgium), B. Bondue (Brussels, Belgium), C. Dahlqvist (Yvoir, Belgium), H. Slabbynk (Antwerpen, Belgium), J. Guiot (Liege, Belgium), G. Joos (Liege, Belgium), N. Gusbin (Liege, Belgium), W. Janssens (Brussels, Belgium), A. Froidure (Brussels, Belgium), W. Wuyts (Leuven, Belgium). Management-related costs of Idiopathic Pulmonary Fibrosis (IPF) in Belgium. 4810

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019 Idiopathic Pulmonary Fibrosis (IPF): Should it be all about the FVC? Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Energy cost of walking : Idiopathic Pulmonary Fibrosis vs COPD Source: Virtual Congress 2020 – Exploring exercise responses in respiratory diseases Year: 2020 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry Source: Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016 Year: 2017 Evaluation of Dyspnea Questionnaires in Patients with Idiopathic Pulmonary Fibrosis (IPF). Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 The European IPF Registry: Addressing challenges and characteristics of patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Idiopathic Pulmonary Fibrosis: mortality trends in Chile Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP) Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE) Source: International Congress 2018 – Aspects of pulmonary rehabilitation and chronic care Year: 2018 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Tuberculosis in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK Source: International Congress 2015 – Latest insights into chronic care Year: 2015